ArticlePloS one2026
hUMSCs-exo@Cyasterone protects the cell model of steroid-induced femur head necrosis by regulating N-glycosylation modification of CTSD-N258A.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIt has been demonstrated that both hUCMSC-exo and Cyasterone exhibit protective effects against steroid-induced osteonecrosis of the femoral head (SIONFH). Additionally, studies have shown that CTSD N-glycosylation influences BMSC apoptosis. Based on these findings, we aim to investigate the mechanism of hUCMSCs-exo@Cyasterone in the Dex-induced BMSCs model of SIONFH, focusing on its regulatory role in CTSD N-glycosylation during apoptosis.
methodsThe SIONFH cell model was induced by dexamethasone (Dex) at a concentration of 10-6mol/L. Experiments with hUMSCs-exo@Cyasterone and CTSD mutants were performed in the BMSC model to analyze proliferation, apoptosis, lysosomal pH, lysosomal membrane permeability, and lysosomal colocalization. Additionally, the expression of apoptosis-related proteins in BMSCs and CTSD in lysosomes and the cytoplasm were examined.
resultsMTT, AO staining, EDU staining, flow cytometry, and confocal microscopy revealed that hUMSCs-exo@Cyasterone attenuated the proliferation of Dex-induced BMSCs and reduced the lysosomal membrane permeability. It also decreased the expression level of apoptosis-related proteins including BID, Caspase-3, and Caspase-1, as well as the levels of CTSD in lysosomal and cytoplasm. CTSD-N258A inhibited BMSC apoptosis, enhanced the protective effect of hUMSCs-exo@Cyasterone, and promoted the lysosomal localization of CTSD and the lysosomal membrane permeability. Moreover, CTSD-N258A helped suppress the expression of apoptosis-related proteins and reduced CTSD expression in cytoplasm and lysosomes.
conclusionhUMSCs-exo@Cyasterone mitigates apoptosis in Dex-induced BMSCs, a cell model of steroid-induced femoral head necrosis, by modulating the N-glycosylation modification of CTSD-N258A.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.